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Abstract
Background: Successful treatment of latent tuberculosis infection (LTBI) is essential to reduce tuberculosis (TB)
incidence rates in low-burden countries. This study measures treatment completion and determinants of non-
completion of LTBI treatment in Norway in 2016.
Methods: This prospective cohort study included all individuals notified with LTBI treatment to the Norwegian
Surveillance System for Infectious Diseases (MSIS) in 2016. We obtained data from MSIS and from a standardized
form that was sent to health care providers at the time of patient notification to MSIS. We determined completion
rates. Pearson’s chi squared test was used to study associations between pairs of categorical variables and separate
crude and multivariable logistic regression models were used to identify factors associated with treatment completion
and adverse drug effects.
Results: We obtained information on treatment completion from 719 of the 726 individuals notified for LTBI treatment in
2016. Overall, 91% completed treatment. Treatment completion was highest in the foreign-born group [foreign-born,
n = 562 (92%) vs Norwegian-born, n = 115 (85%), p = 0.007]. Treatment completion did not differ significantly between
prescribed regimens (p = 0.124). Adverse events were the most common reason for incomplete treatment. We found no
significant differences in adverse events when comparing weekly rifapentine (3RPH) with three months daily isoniazid
and rifampicin (3RH). However, there were significantly fewer adverse events with 3RPH compared to other
regimens (p = 0.037). Age over 35 years was significantly associated with adverse events irrespective of regimen
(p = 0.024), whereas immunosuppression was not significantly associated with adverse events after adjusting for other
variables (p = 0.306). Treatment under direct observation had a significant effect on treatment completion for foreign-
born (multivariate Wald p-value = 0.017), but not for Norwegian-born (multivariate Wald p-value = 0.408) individuals.
Conclusions: We report a very high treatment completion rate, especially among individuals from countries with high
TB incidence. The follow-up from tuberculosis-coordinators and the frequent use of directly observed
treatment probably contributes to this. Few severe adverse events were reported, even with increased age
and in individuals that are more susceptible. While these results are promising, issues of cost-effectiveness and
targeting treatment to individuals at highest risk of TB are important components of public health impact.
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Background
Treatment of latent tuberculosis infection (LTBI) in
groups at high risk for tuberculosis (TB) disease is a
cornerstone in the global strategy to eliminate TB [1].
Norway has a mandatory screening program for TB and
LTBI, which includes immigrants from high TB inci-
dence countries, pre-employment screening, and out-
break management [2]. In addition, LTBI management is
recommended prior to iatrogenic immunosuppression.
In 2016, immigrants under the age of 35 from countries
with TB incidence rates (IR) > 40 per 100,000 population
(as estimated by WHO) were eligible for screening with
IGRA (or equivalent) upon arrival in Norway. In
addition, immigrants > 15 years of age were screened for
TB with a chest X-ray. In Norway’s national guidelines,
LTBI treatment is strongly recommended for children
under the age of 5, contacts, those with fibrotic lesions
on chest X-ray, or those with select immunosuppressive
conditions (HIV-infection, haemodialysis, solid organ
transplants, malignancies, or prior to iatrogenic im-
munosuppression). LTBI treatment is conditionally rec-
ommended for children aged 5–14 years, those with
calcifications on chest X-ray, those who are underweight,
and individuals with long-term steroid treatment, dia-
betes mellitus, or drug addiction. Being foreign-born
was not considered a single criterion for priority for
treatment at the time of the study [3].
The use of LTBI treatment has rapidly increased in
Norway in recent years, stabilizing at around 750 cases
per year [4, 5]. Individuals prescribed LTBI treatment are
reported to the Norwegian Surveillance System for Infec-
tious Diseases (MSIS) [6]. However, treatment completion,
an important indicator of the impact, safety, and cost ef-
fectiveness of the screening program, is not routinely
reported.
LTBI treatment completion rates vary considerably
across risk-groups and settings [7], and long duration and
adverse events are well-known barriers to treatment com-
pletion [7–12]. A Norwegian study from 2009 found over-
all high LTBI treatment completion, and no adverse
events requiring hospital admission [13]. Since then,
Norwegian guidelines have increasingly targeted groups at
high risk for TB reactivation, including older individuals
with more comorbidities and recent immigrants to
Norway [3]. Recent immigrants are often difficult to
follow-up due to their mobility and a lack of government-
issued identification numbers [14, 15]. Additionally, the
increasing use of immunosuppressants may pose new
challenges to LTBI treatment strategy.
The most common LTBI regimen is a daily combination
of rifampicin and isoniazid for three months (3RH). The
increasing use of weekly-administered rifapentine (3RPH)
[8], a newer and less-studied regimen, highlights the need
for strengthened LTBI treatment surveillance. National
guidelines currently recommend directly observed treat-
ment (DOT) for this new 3RPH regimen.
Severe adverse events due to preventive treatment are
primarily related to isoniazid induced peripheral neur-
opathy and hepatotoxicity, with higher rates found in
those aged > 35 years [12, 16], and hepatotoxicity, gastro-
intestinal intolerance, and hypersensitivity from rifamycins
[12]. We question whether tolerance to adverse effects
may be context specific, with lower tolerance in a country
where TB is rare. If significant scale-up of LTBI treatment
is indicated, information about adverse events and treat-
ment completion by regimen will be highly relevant.
In Norway, prescription of TB drugs, including LTBI
treatment, is the responsibility of pulmonologists, infec-
tious disease specialists, or paediatricians who work pri-
marily in hospital settings. The role of “TB coordinator”
was introduced in the national TB control programme
in 2003 to strengthen patient support and coordinate TB
control between all healthcare levels [2]. One key re-
sponsibility of the coordinator is to establish a treatment
plan for every individual starting TB treatment. The plan
clearly states the responsibilities of all partners involved
and seeks to maximize patient-involvement.
The objective of this study is to measure LTBI treatment
completion and determinants of non-completion in all in-
dividuals notified to MSIS in 2016. We also assess the risk
of severe adverse events related to treatment, and their
consequences for the LTBI treatment strategy, and explore
the use of associated healthcare resources.
Methods
Study participants
This is a nationwide prospective cohort study, includ-
ing all individuals reported with LTBI treatment to
MSIS between January 1, 2016 and December 31, 2016.
The protocol is available as supplementary material
(Additional file 1:). Data included demographic and
clinical information available through MSIS, and add-
itional data on treatment completion, adverse events,
patient support, and use of healthcare resources col-
lected through a standardized treatment completion
form that was sent to prescribing clinicians and TB co-
ordinators at the time the individual was reported to
MSIS (form with translation, see Additional file 2: a, b).
If the form was not returned, we sent one reminder by
mail before calling the prescribing clinician or respon-
sible TB coordinator. If multiple forms were returned
for the same individual, we verified conflicting data
with a call to the responsible physician or TB coordin-
ator. If we were unable to verify conflicting data, such
as the number of visits with a physician or TB coordin-
ator, we calculated the mean value of the reported data
before inclusion in the analyses.
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Definitions
LTBI treatment completion was measured as reported
by the responsible clinician, and verified by the duration
of treatment (measured in days) for the different regi-
mens. Information on adverse events was only reported
if it led to interruption (treatment was stopped tempor-
arily, but later continued) or termination (stopped com-
pletely) of treatment. Severity of hepatotoxicity was
based on reported increase in the liver enzymes alanine
aminotransferase (ALAT) and aspartate transaminase
(ASAT) and bilirubin in blood samples. Severity was
classified by upper limits of normal values (ULN) for
serum levels of ALAT or ASAT, consistent with the
Common Terminology Criteria for Adverse Events
(CTCAE4) [17]: grade 1 (>ULN -3.0 x ULN), grade 2
(> 3.0–5.0 x ULN), grade 3 (> 5.0–20.0 x ULN), and grade
4 (> 20.0 x ULN). Other blood test results were not rou-
tinely collected. Remaining adverse events were classified
by their clinical symptoms.
Statistical analysis
We used STATA 2015 for statistical analysis. We present
descriptive statistics for continuous variables as means
and standard deviations for symmetrical data, and me-
dians and interquartile range (IQR) for skewed data.
Pearson’s chi squared or Fisher’s exact test, as appropri-
ate, assessed associations between pairs of variables.
Additionally, we ran two separate logistic regression
models. The first model analysed the association be-
tween treatment non-completion and origin (Norwe-
gian-born/foreign-born), age (>/< 35 years), gender, and
type of treatment support (self-administered treatment/
daily DOT/weekly DOT). Treatment regimen could not
be included in the model because of its association with
DOT. Similarly, we could not include both establish-
ment of treatment plan and use of DOT in the model
because the two are related. The final model did not in-
clude either the establishment of a treatment plan or im-
munosuppression because these were not found to be
significantly associated with treatment completion in
crude analyses.
To investigate if the association between treatment
non-completion and treatment support was modified by
age, sex, or origin we ran separate models. We ran the
baseline model (treatment non-completion = treatment
support + origin + age + sex) and then subsequently
tested for interaction between treatment support and
age, sex, or origin, i.e. (treatment support*age)/ (treat-
ment support*sex)/ (treatment support*origin). We then
performed likelihood ratio tests comparing the separate
models to the baseline model. We found no statistically
significant effect of age or sex on treatment support. We
found a significant effect of origin on treatment support
and therefore stratified the effect of treatment support
on treatment non-completion by origin in the model.
We also tested for an interaction between origin and age
and origin and sex. No such interactions were identified.
Information on age and origin was complete. Informa-
tion on treatment completion was missing for six indi-
viduals, and treatment support was missing for 13. Since
missing information is unlikely random, we used mul-
tiple imputations to investigate the effect of missing data
on the model. We imputed five datasets using chained
equations (“mi impute chained” command) and recre-
ated the complete-case analyses using the imputed data.
The second model analysed the association between
interruption or termination of treatment because of
adverse events (yes/no), and treatment regimens
(3HR/3RPH/Other), age (>/< 35 years), and immunosup-
pression (yes/no). One individual had missing information
for treatment regimen, and for this person we coded treat-
ment regimen as “other”.
To investigate if the association between adverse events
and treatment regimen was modified by age or immuno-
suppression, we ran two models. We ran the baseline
model (adverse effect = treatment regimens + age + im-
munosuppression) and subsequently tested for interaction
between treatment regimens and age or immunosuppres-
sion, i.e. (treatment regimens*age)/ (treatment regimen-
s*immunosuppression). We also ran a model investigating
whether there was an interaction between age and
immunosuppression, i.e. (age*immunosuppression). We
then performed likelihood ratio tests comparing the separ-
ate models to the baseline model. We found no statisti-
cally significant effect of age or immunosuppression on
treatment regimens. We could not test the interaction be-




In 2016, MSIS received 747 notifications of the prescrip-
tion of LTBI treatment. We later excluded 21 cases be-
cause the treatment was completed in 2015 (delay in
reporting), which left 726 individuals for follow-up in
the prospective cohort. Table 1 presents baseline charac-
teristics of the study population by origin.
Eighteen percent of the individuals (n = 131) were
Norwegian-born and 82% (n = 595) were foreign-born. In-
formation on country of birth was missing for four indi-
viduals. Among foreign-born, 197 (33%) were born in a
country with a WHO estimated [18] TB incidence rate
(IR) of > 200 per 100,000 population, Table 1. Forty-three
percent of immigrants (n = 253) had no additional risk
factors for TB progression other than being foreign-
born. Of these, 94 (35%) arrived from countries with
TB IR < 150, 66 (52%) with IR 150–200, and 91
(46%) with IR > 200 per 100,000 population (2
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missing). In total, 314 (53%) of the immigrants had lived
in Norway for less than one year at the time of notifica-
tion, and were therefore classified as recent immigrants.
The Norwegian-born group was more likely to be part
of contact tracing, have at least one medical risk factor,
and have a negative interferon-gamma release assay result
(IGRA; QuantiFERON TB-Gold (QFT®)) prior to treat-
ment onset, Table 1. Age distribution differed between
Norwegian and foreign-born, with a higher proportion of
either young or old patients in the Norwegian-born group.
3RH (55%) was the most common regimen, although the
use of the newest regimen, 3RPH (42%), was frequent, and
its use increased over the study period. The 3RPH regi-
men was more commonly prescribed among foreign-born
(46%) compared to Norwegian-born (23%).
Treatment completion
Information on treatment completion was obtained for 719
(99%) of the individuals who started LTBI treatment. Table 2
presents treatment completion and the reasons for not
completing treatment. Overall, 91% completed their treat-
ment course as reported by the prescribing physician.
Treatment completion did not differ significantly for
different regimens (p = 0.124). Foreign-born individuals
were more likely to complete treatment compared to
Norwegian-born [foreign-born, n = 562 (92%) vs
Norwegian-born, n = 115 (85%), p = 0.007]. They were
also more likely to be prescribed with 3RPH [foreign-born,
n = 276 (46%) vs Norwegian-born n = 30 (23%) p-value
0.001], a regimen for which DOT is recommended.
Foreign-born individuals were also more likely to be
treated under DOT, even for regimens for which DOT is
not routinely recommended [foreign-born, n = 151 (47%)
vs Norwegian-born n = 28 (28%) p = 0.002]. Among recent
immigrants, 294 (94%) completed their treatment, 48%
Table 1 Baseline characteristics of the study population by











Male 69 (53) 358 (60) 427 (59)
Age at notification > 0.001
< 5 years 37 (28) 25 (4) 62 (9)
5–14 years 10 (8) 132 (22) 142 (20)
15–34 years 33 (25) 315 (53) 348 (48)
35–64 years 36 (27) 115 (19) 151 (21)
> 65 years 15 (11) 8 (1) 23 (3)
Risk groupsa
Any risk factora 121(92) 342 (58) 463 (64)
Recent exposure, contacts 68 (52) 95 (16) 163 (22) > 0.001
Contacts < 5 years 35 (27) 3 (0.5) 38 (5)
Positive chest X-ray, any 7 (5) 60 (10) 67 (9) 0.090
Fibrotic lesions 2 (2) 17 (3) 19 (3) 0.388
Immunosuppressive
condition
51 (39) 72 (12) 123 (17) > 0.001
HIV infection – 12 (2) 12 (2)
Chronic renal disease 1 (1) 4 (1) 5 (1)




13 (10) 10 (2) 23 (3)




Positive 94 (72) 577 (97) 671 (92)
Negative 15 (11) 5 (1) 20 (3)
Inconclusive 2 (2) – 2 (0)
Missing or unknown 20 (15) 13 (2) 33 (5)
Regimen > 0.001
3RH dailyI 97 (74) 302 (51) 399 (55)
3RPH weeklyII 30 (23) 276 (46) 306 (42)
4R or 6H monotherapy
dailyIII
3 (2) 15 (3) 18 (2)
OtherIV – 2 (0) 2 (0)
Missing 1 (1) – 1 (0)
TB IR (per 100,000) in country of birth#
< 150 na 267 (45) 267 (45)
150–200 na 127 (21) 127 (21)
Table 1 Baseline characteristics of the study population by






> 200 na 197 (33) 197 (33)
Missing na 4 (1) 4 (1)
Data are presented as n (%) or median [interquartile range]. % refers to columns
and not rows
aAccording to Norwegian guidelines for the management and control of tuberculosis:
with strong or conditional recommendation for LTBI treatment (age< 15 years, known
exposure, positive chest X-ray or immunosuppressive condition)
bIncludes rheumatologic-, dermatologic-, neurologic- and gastroenterological
medical conditions
cOther medical conditions include unspecified immunosuppressive conditions
reported by the clinician
I3RH: rifampicin (R) and isoniazid (H) daily for three months
II3RPH: rifapentine (RP) and isoniazid (H) in 12 weekly doses
IIIRifampicin (R) monotherapy daily for four months or isoniazid (H)
monotherapy daily for six months
IVOthers include full-course TB treatments for two individuals for two and four
months respectively
# Four immigrants had missing information on country of birth
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were prescribed with 3RPH, and 65% were treated under
DOT while on regimens other than 3RPH.
In crude logistic regression models, origin, age, sex,
and treatment support were significantly associated with
treatment non-completion. In a multivariable logistic re-
gression model, we found that neither origin, age over
35 years, or sex were significantly associated with treat-
ment non-completion. However, the effect of treatment
support was modified by origin, with significantly lower
risk of non-completion with daily and weekly DOT com-
pared to self-administration in the foreign-born group.
Treatment support had no significant effect on treat-
ment completion in the Norwegian-born group, Table 3.
We ran a sensitivity analysis by rerunning the analyses
in Table 3 with a multiple imputed dataset (using
chained equations). The sensitivity analysis showed no
impact on the overall results, and the results are avail-
able as supplementary material (Additional file 3).
Adverse events
Adverse events was the most common reason reported
for incomplete treatment in all groups. The total num-
ber of adverse events according to the study definitions
was 47 (6.5%). In total, 41 (5.6%) individuals terminated
treatment, Table 2, and an additional six (0.8%) individ-
uals interrupted treatment to control adverse events but
later continued and completed treatment. These six indi-
viduals are recorded as complete treatment in Table 2.
Three of these temporary interruptions (3RH) were due
to hepatotoxicity (one grade 2 and two grade 3), two
were due to gastrointestinal symptoms, (3RPH and H)






Number of individuals 399 306 21 726
Duration of treatment (days), median [IQR]* 90 [73–156] 77 [70–98] – –
Treatment completion
Completed according to physiciana 357 (89.5) 284 (92.8) 17 (80.9) 658 (90.6)
Missing information 3 (0.8) 4 (1.3) – 7 (1.0)
Incomplete treatment 39 (10) 18 (5.9) 4 (19.0) 61 (8.4)
Reasons for incomplete treatment
LTBI excluded 4 (1.0) – – 4 (0.6)
Diagnosed with TB disease 1 (0.3) – 1 (0.1)
Patient choice 4 (1.0) 2 (0.7) – 6 (0.8)
Lost to follow-up 1 (0.3) 3 (1.0) – 4 (0.6)
Other or unknown 3 (0.8) 2 (0.7) 5 (0.7)
Termination due to adverse effectsb 26 (6.5) 11 (3.4) 4 (19.0) 41 (5.6)
Hepatotoxicity (grade 1–2)c 8 (2.0) – – 8 (1.1)
Hepatotoxicity (grade 3–4)c 5 (1.6) 2 (0.7) 1 (4.8) 8 (1.1)
Gastrointestinal symptoms 10 (2.5) 8 (2.6) 2 (9.5) 20 (2.8)
Fatigue 6 (1.5) 8 (2.6) 1 (4.8) 15 (2.1)
Flu-like symptoms 2 (0.5) 4 (1.3) 1 (4.8) 7 (1.0)
Skin rash 2 (0.5) 1 (0.3) 1 (4.8) 4 (0.6)
Peripheral neuropathy 1 (0.3) 1 (0.1)
Joint pain – 2 (0.6) – 2 (0.3)
Other symptomsd 2 (0.5) 3 (1.0) 2 (9.5) 7 (1.0)
Data are presented as n (%) or median [interquartile range]
I3RH: rifampicin (R) and isoniazid (H) daily for three months
II3RPH: rifapentine (RP) and isoniazid (H) in 12 weekly doses
IIIOther: rifampicin (R) monotherapy daily for four months (n = 5), Isoniazid (H) monotherapy for six months (n = 13) or combination therapy for TB disease (n = 2)
and missing information about drug regimen (n = 1)
*Duration of treatment for those where the clinician reported the treatment as completed
aThe responsible clinician reported that the planned treatment was completed
bMany reported more than one adverse effect
cSeverity of hepatotoxicity was classified according to Common Terminology Criteria for Adverse Events (CTCAE), ULN = upper limits of normal value for serum
levels of liver function, grade 1 (>ULN -3.0 × ULN), grade 2 (> 3.0–5.0 × ULN), grade 3 (> 5.0–20.0 × ULN), and grade 4 (> 20.0 × ULN)
dIncludes headache, sleep disorder, and unstable international normalized ratio (INR) for prothrombin time
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and one to fatigue (3RPH). The duration of the interrup-
tion was 2, 4, 7, 22, 28 and 113 days respectively.
In a multivariable logistic regression model, we found
that regimen was borderline associated with adverse
events (p-value = 0.065). There were no significant differ-
ences when comparing 3RH vs 3RPH, nor 3RH vs Other
(R or H monotherapy or full course TB treatment).
However, there were significantly fewer adverse events
with 3RPH compared to "other" regimens (p = 0.037).
Age over 35 years was significantly associated with hav-
ing more adverse events, even after adjusting for regi-
men, whereas immunosuppression was not significantly
associated with having adverse events after adjusting for
other variables, Table 4. No deaths were reported.
Duration of treatment prior to termination ranged from
2 to 122 days, with a median of 25 days (IQR 6–84). For
the two 3-month regimens combined (3RH +3RPH), 61%
of those who terminated treatment completed less than
half of the prescribed regimen.
Among those who met the study-definition for adverse
effects, 22 (47%) had one symptom, 16 (34%) had two,
and nine (19%) had three. There was no significant dif-
ference in number of symptoms reported between those
who interrupted and those who terminated treatment
(p = 0677). Gastrointestinal symptoms was the most
common complaint in both age groups, followed by hep-
atotoxicity and fatigue, Table 2. Two individuals were
classified with grade 4 hepatotoxicity. One was a child
who was diagnosed with toxic hepatitis after two weeks
of LTBI treatment. Treatment was immediately stopped,
allowing transaminase values to normalize, and the pa-
tient fully recovered. The other was a middle-aged indi-
vidual who developed hepatotoxicity with high
transaminase values after eight weeks of LTBI treatment.
Table 3 Associations between the outcome of treatment non-
completion and the variables treatment support, origin, age and
sex (n = 726)
Covariates Univariable Multivariable
n c OR p a OR SE p 95% CI
Origin
Foreign-born 595 1 (ref) 1(ref)
Norwegian-born 131 2.1 0.016 0.8 0.342 0.602 0.34–1.84
Age group
< 35 561 1 (ref) 1 (ref)
> 35 years 165 1.9 0.026 1.7 0.521 0.093 0.92–3.09
Sex
Female 299 1 (ref) 1 (ref)
Male 427 0.5 0.017 0.6 0.093 0.106 0.36–1.10
Treatment support. Model with interaction term for origin: LRT p-value
of interaction term = 0.049
Effect of treatment support on treatment completion in foreign-born
(multivariate wald p-value 0.017)
Self-administereda 174 1 (ref) 1 (ref)
DOT dailyb 151 0.2 0.005 0.3 0.150 0.017 0.10–0.80
DOT weeklyc 261 0.4 0.009 0.4 0.162 0.027 0.22–0.91
Effect of treatment support on treatment completion in Norwegian-born
(multivariate wald p-value 0.468)
Self-administereda 80 1 (ref) 1 (ref)
DOT dailyb 28 1.7 0.374 2.1 1.332 0.229 0.62–7.26
DOT weeklyc 19 0.9 0.928 1.0 0.868 0.961 0.20–5.34
OR Odds ratio, SE standard error, DOT Direct Observed Treatment for part of or
the full treatment period
aSelf-administered include those who managed their treatment themselves or
were given weekly pill boxes
bdaily DOT: those who were administered daily treatment under direct observation
cweekly DOT: those who were administered weekly rifapentine and isoniazid
under direct observation
Table 4 Associations between adverse eventsa, regimen, age, and immunosuppression, n = 726
Covariates Univariable Multivariable
n c OR p a OR SE p 95% CI
Regimen (Wald test for overall variable in adjustment model, p = 0.065)
3RHb 399 1 (ref) 1 (ref)
3RPHc 306 0.57 0.097 0.60 0.209 0.141 0.30–1.18
Otherd 21 3.99 0.012 2.37 1.360 0.131 0.78–7.30
Age
< 35 yrs 561 1 (ref) 1 (ref)
> 35 yrs 165 3.62 < 0.001 2.51 2.25 0.024 1.13–5.60
Immunosuppression
No immunosuppression 603 1 (ref) 1 (ref)
Immunosuppression, any 123 3.39 < 0.001 1.55 0.66 0.306 0.67–3.57
OR Odds ratio, SE standard error
aAdverse effects leading to termination or interruption of treatment, n = 47
b3HR, 3 months daily rifampicin and isoniazid
c3RPH, 12 weekly doses of rifapentine and isoniazid
dOther; rifampicin monotherapy (n = 5), isoniazid monotherapy (n = 13), combination therapy for TB disease (n = 2) and 1 missing information
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The treatment was immediately stopped, and transamin-
ase values normalized after six weeks. Both individuals
received 3RH regimen and were managed as outpatients.
Additionally, eight individuals were classified as having
hepatotoxicity grade 3. Two of these were hospitalized
due to complex comorbidities. The remaining were
treated as outpatients, and transaminase values normal-
ized after treatment was stopped. The 3RH regimen was
prescribed in 16 out of 19 (84%) patients who inter-
rupted or terminated treatment due to hepatotoxicity.
Patient support, drug administration, and use of
healthcare resources
A treatment plan was established prior to treatment for
655 (90%) individuals. Foreign-born individuals were
more likely to have a treatment plan compared with
Norwegian-born individuals (n = 544, 91% vs n = 111,
85%, p 0.017).
DOT, either for part of or the whole treatment period,
was reported in 173 (43%) of individuals prescribed with
3RH, in 280 (92%) with 3RPH, and in six (29%) with
“other”, Table 5. Home-visiting nurses provided DOT in
324 (71%) cases, the family in 11 (2%), and outpatient
hospital clinics, assisted living facilities, refugee centres,
work places, or general practitioners in 57 (12%). Infor-
mation about the DOT provider was missing for 65
(15%) individuals.
The median number of consultations with a medical doc-
tor was 1.5 (IQR 1–8, range 1–11), and 1.5 (IQR 0–7, range
0–14) with nurse. Almost half (48%) had only one consult-
ation with a doctor. We found no significant difference in
the mean number of consultations with a doctor or nurse
between foreign-born and Norwegian-born individuals.
Among the 658 individuals who completed treatment, 397
(60%) had their last consultation in the hospital before
(n = 334, 51%), or at the time of treatment initiation
(n = 63, 9%). Only 193 (29%) had a consultation in the hos-
pital more than six weeks after the treatment start date.
Discussion
This one-year prospective study found a 91% LTBI treat-
ment completion rate in Norway. Treatment completion
did not differ significantly by regimen. Completion was
higher among foreign-born than Norwegian-born indi-
viduals. Treatment under DOT had a significant effect
on treatment completion for foreign-born individuals,
but not in the Norwegian-born group. The primary rea-
son for not completing treatment was adverse events.
The majority of these were mild to moderate in severity,
although medically significant (grade 3) and severe
(grade 4) hepatotoxicity led to termination of treatment
in 1.1% of participants. Few individuals were lost to
follow-up. Individual treatment plans were established
for the majority, and DOT was common, even with regi-
mens where this is not routinely recommended.
Treatment completion
The treatment completion rate of 91% is consistent with
the 89% previously reported in Norway [13]. Direct com-
parison with previous studies is difficult due to differ-
ences in study designs, regimens, and the populations
under study. Completion rates are commonly reported
as inversely related to treatment length [7]. Unsuper-
vised six to nine months of isoniazid treatments in the
US have shown around 50% completion rates [10, 11,
19, 20], 3–4 months RH regimens are reported at 85–
90% [13, 21–23] and recent studies report similarly high
completion rates with weekly (supervised) 3RPH admin-
istration [24–28]. Our results are consistent with a 2017
review [29] reporting no important differences in effi-
cacy and completion rates for the 3RPH regimen when
compared to other regimens. The review, however, did
support a higher likelihood of completion with a shorter
regimen. Additionally, lower loss to follow up has been
associated with immunocompromised patients, being
part of a contact investigation, and the shorter,
rifamycin-based regimens [30].
Our high completion rate is surprising given that the
majority of patients were recent arrivals to Norway and
were born in countries with a high TB prevalence, factors
often associated with poor access and adherence to health
services. A Swedish study reported 76% LTBI treatment
completion over a six year period (2002–2007) overall, but
only 68% completion among recent immigrants, (< 1 years
residence) with immigrants of Somali origin having the
lowest completion rates [23]. Similarly in Japan, a study
reported significantly higher completion rates in Japanese
versus foreign-born individuals [31]. In our setting, the
most recent immigrants completed treatment at a higher
rate than other immigrants, and immigrants as a whole
completed treatment to a higher extent than
Norwegian-born individuals. This finding is unexpected
because immigrants in Norway tend to under-utilize other
Table 5 Drug-administration by regimen, n = 726
Drug administration 3RHa daily 3RPHb weekly Otherc Total
Number of individuals 399 (100) 306 (100) 21 (100) 726 (100)
Self-administered 220 (55) 20 (7) 14 (67) 254 (35)
Direct observed treatment
Whole period 132 (33) 269 (88) 3 (14) 404 (56)
Part of period 41 (10) 11 (4) 3 (14) 55 (8)
Missing information 6 (2) 6 (2) 1 (5) 13 (2)
Data are presented as n (%)
arifampicin (R) and isoniazid (H) daily for three months
brifapentine (RP) and isoniazid (H) in 12 weekly doses
cIrifampicin (R) monotherapy daily for four months (n = 5), Isoniazid (H) monotherapy
for six months (n = 13) or combination therapy for TB disease (n = 2) and missing
information (n = 1)
dOther included: hospital outpatient clinic, assisted living facilities, refugee centres,
work-places or with general practitioners.
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preventive health services, such as mammography [32].
Foreign-born individuals in this study were more likely to
have a treatment plan established prior to LTBI treatment,
be treated under direct observation, and were more com-
monly prescribed the 3RPH weekly regimen compared to
Norwegian-born individuals. These findings may explain
such high rates of completion among recent immigrants.
Treatment support, which was coded separately for daily
or weekly DOT to reflect treatment regimens, was signifi-
cantly associated with treatment completion among
foreign-born individuals when controlling for other
co-variates. However, we were unable to control for ad-
verse effects as a co-variate in the analyses, since this in-
formation was only recorded when not completing
treatment.
Another explanation may be the role of TB coordina-
tors, mostly specialized nurses, which is unique in a
northern European setting. The TB coordinators are ac-
tively involved in implementation of TB control activities,
both on individual and system levels. They know their pa-
tients well, and this may mitigate loss to follow-up. Previ-
ous studies have shown that social interventions such as
adherence coaching, contingency contracting, enhanced
outreach, and home visits improve treatment completion
and may benefit patients who are at risk of progressing to
active TB [33, 34]. In Norway, such activities are initiated
by TB coordinators.
Adverse events
Adverse events was the most common reason for not
completing treatment in both the Norwegian and
foreign-born groups. This is consistent with other stud-
ies [35]. The proportion of individuals who discontinued
LTBI treatment due to side-effects (5.6%) in this study is
similar to the 7.6% reported in the Netherlands [21], 6.4
and 5.9% reported in the USA [35], and 7% reported in
Norway in 2009 [13], but lower than the 12% reported
from Australia [36]. Similarly, a recent study in Taiwan
that compared treatment completion and cost effective-
ness for 3RPH versus H reported higher completion in
the 3RPH regimen due to the shorter treatment period
and reduced likelihood of severe side effects [37]. This is
also consistent with our results.
The severity of reported adverse events varied. Since the
treatment is preventive rather than curative, mild to mod-
erate side effects may influence both the patient’s and the
doctor’s motivation to continue treatment. The rate of
clinically significant and severe hepatotoxicity (grade 3
and 4) reported in this study (1.1%) is lower than a median
rate of 1.8% (range 0.1–11.9%) reported in a study on
age-related hepatotoxicity following 6-9 months of isonia-
zid [16]. In accordance with other studies, we found a
higher rate of grade 3 and 4 hepatotoxicity with increasing
age [7, 16, 36], lower rates with 3RPH compared with
other regimens [20, 26, 35, 38], rare need for
hospitalization, and no deaths [13, 16, 27, 36, 39, 40].
Patient support and use of health care resources
Norway’s high completion rate must also be seen in rela-
tion to the resources used to achieve it. Two elements
that make preventive treatment in Norway relatively
costlier than elsewhere are the frequent use of DOT and
the highly specialized care levels. Almost two thirds of
the patients involved in the study received treatment
under DOT. Norwegian guidelines do not routinely rec-
ommend DOT for treatment regimens other than 3RPH.
The increasing use of this 12-dose regimen (3RPH), with
weekly administration rather than a prolonged daily regi-
men, will reduce DOT associated costs. Further, a recent
randomized clinical trial found that there was not a sig-
nificant difference in completion rates for directly ob-
served 3RPH versus self-administered 3RPH treatment,
which may change current recommendations for super-
vised 3RPH treatment [41].
Providing preventive treatment through subspecialist
physicians rather than primary care is costly. How-
ever, training a larger group of primary care doctors
about the details of TB and its prevention and treat-
ment in low incidence settings such as Norway would
require substantial effort. The greatest cost, as well as
the greatest benefit, may be attributable to having
dedicated TB coordinators. In the current study, 90%
of patients had treatment plans established by TB
coordinators.
Strengths and limitations
The strengths of the study include the population-wide
approach, the comprehensive information available for
every individual, the standardized classification of sever-
ity of hepatotoxicity, and our very low rate of loss to
follow-up. The sensitivity of our reporting system for
LTBI treatment is assumed to be high since information
on TB-related prescriptions is collected independently,
and missing data is routinely monitored to ensure
complete information.
Limitations include that completion rates and adverse
events for the various regimens may reflect systematic dif-
ferences in treatment assignment and clinician assessment
rather than differences in the regimens themselves. We
have, when possible, adjusted for this in our analyses.
Judgment of treatment completion was made by the
treating physician, often based on only one consultation at
the beginning of the treatment course, in addition to in-
formation received from the TB coordinator and the
DOT-provider. The question about completion was, how-
ever, followed up with a statement of the number of days
on treatment and overseen by the TB coordinator. Ad-
verse drug events that did not lead to interruption or
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termination of treatment were not recorded. Therefore,
we could not control for this as a co-variate. We may have
also missed some adverse effects and mild degrees of
toxicity.
Conclusions
This study indicates that with well-organized health
services, high LTBI treatment completion is possible, even
in high-risk immigrant groups. We report high treatment
completion across all subgroups. Treatment completion is
the end-point of Norway’s LTBI screening strategy. Know-
ledge of the treatment completion rate and adverse events
are crucial in the assessment of the screening program’s
impact and cost effectiveness. Although adverse events
were the primary determinants of treatment non-comple-
tion, our results seem reassuring, even for more elderly
and immunocompromised individuals, given adequate
monitoring and follow-up during treatment. While this
study has shown that DOT is very effective in ensuring
treatment completion among hard to reach populations,
further research is necessary to evaluate best practices
from a cost-effectiveness standpoint.
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